Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
OVOvid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID)

NASDAQ Global Select · Currency in USD
$2.16 ▼ -0.21 (-8.86%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.19 ▲ +0.03 (+1.55%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$2.37
Open
$2.31
Day's Range
$2.12 – $2.32
52 Week Range
$1.18 – $3.11
Volume
2,017,136
Avg. Volume
2,125,084
Market Cap
$421.84M
Beta (5Y Monthly)
0.23
PE Ratio (TTM)
--
EPS (TTM)
-$0.47
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.25

Profile: Ovid Therapeutics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
23
CEO
Margaret Alexander
Website
ovidrx.com

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.08 · Revenue est. $31.09K
DateEst.Actual
Aug 13, 2026-$0.12-$0.08Beat
May 12, 2026-$0.12-$0.12Beat
Mar 18, 2026-$0.10$0.06Beat
Nov 12, 2025-$0.15-$0.17Miss
Aug 13, 2025-$0.16-$0.06Beat
May 13, 2025-$0.14-$0.14Beat

Analyst view

Consensus price target
$6.25 ▲ +189.4%
Range $5.00 – $8.00
Rating: Buy
Buy 79% · Hold 21% · Sell 0%

Get free alerts on OVID and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.